|
ETFMG Treatments, Testing and Advancements ETF | GERM | Global X Blockchain ETF | BKCH | Global X Artificial Intelligence & Technology ETF | AIQ | Point Bridge America First ETF | MAGA | Chevron Corp | CVX | Global X Cybersecurity ETF | BUG | Tenable Holdings Inc | TENB | Constrained Capital ESG Orphans ETF | ORFN | Philip Morris International Inc | PM | Nextera Energy Inc | NEE |
Gross Expense Ratio*
0.68%
SEC 30 Day Yield (as of 04/28/23 )
--
Ann. Dividend/Yield
$0.2286/1.13%
Ex-Dividend Date
3/22/2023
52-Wk Range
17.74 - 27.55
Fund Inception
06/17/2020
|
 Loading...
The chart is currently unavailable.
|
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the Prime Treatments, Testing and Advancements Index.The index tracks the performance of U.S.-listed equity securities or depositary receipts of companies that (i) perform research, development, and commercialization of treatments or vaccines for infectious diseases or (ii) engage in the research, development, manufacturing, and provision of biological tests for patients. The fund invests at least 80% of its total assets in the component securities of the index. The fund is non-diversified.
|
Market Return % (as of 04/30/2023) |
NAV Return % (as of 04/30/2023) |
Market Return % (as of 03/31/2023) |
NAV Return % (as of 03/31/2023) |
1-Month |
+1.54% |
-0.74% |
-2.77% |
-3.10% |
3-Month |
-12.55% |
-13.46% |
-8.26% |
-8.56% |
6-Month |
-7.63% |
-7.10% |
-0.82% |
+2.02% |
Year-to-date |
-6.85% |
-9.24% |
-8.26% |
-8.56% |
1-Year |
-9.56% |
-9.16% |
-24.49% |
-22.26% |
3-Year |
-- |
-- |
-- |
-- |
5-Year |
-- |
-- |
-- |
-- |
10-Year |
-- |
-- |
-- |
-- |
Since Inception |
-5.76% |
-5.40% |
-6.44% |
-5.30% |
Inception Date: June 17, 2020
Performance Details
Total return reflects performance without adjusting for sales charges or the effects of taxation, but is adjusted to reflect all actual ongoing fund expenses and assumes reinvestment of dividends and capital gains. If adjusted, sales charges would reduce the performance quoted. Performance data quoted represents past performance, is no guarantee of future results, and may not provide an adequate basis for evaluating the performance potential of the product over varying market conditions or economic cycles. Current performance may be higher or lower than the performance data quotes. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost.
|
Market Return % (as of 04/30/2023) |
NAV Return % (as of 04/30/2023) |
Market Return % (as of 03/31/2023) |
NAV Return % (as of 03/31/2023) |
1-Year |
-9.56% |
-9.16% |
-24.49% |
-22.26% |
5-Year |
-- |
-- |
-- |
-- |
10-Year |
-- |
-- |
-- |
-- |
Since Inception |
-5.76% |
-5.40% |
-6.44% |
-5.30% |
Inception Date: June 17, 2020
Cyclical |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
Defensive |
100.00% |
0.00% |
100.00% |
0.00% |
Sensitive |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
Portfolio Details
|
* represents an International company or one without a recognizable symbol.
Portfolio Details
|
|
|